Abstract
Purpose
This study intends to provide new insights into the incidence and care of mucositis by the epidemiological characterization of patients with hematological malignancy treated at our institution. It also aims to understand the effectiveness of several treatments used.
Methods
This is a longitudinal observational single-center study—convenience sample—which includes malignant hematologic inpatients submitted to high-dose CT from February to August 2012. We registered epidemiological data, diagnosis, oral mucositis daily questionnaire (OMDQ), World Health Organization (WHO) oral toxicity scale, and supportive medications used for mucositis.
Results
We evaluated 30 patients who had 73 episodes of hospitalization, having recorded the development of mucositis in 21.9 % (n = 16) episodes (22 patients with acute leukemia (AL) and 8 patients with non-Hodgkin lymphoma (NHL)). Grades 3–4 mucositis was reported in 4.1 % of the total episodes. The results of OMDQ showed some limitations in the quality of life, of patients with mucositis, related with the ability to eat and drink due to mouth pain (p < 0.001). In patients with NHL and AL, neutropenia entails an increased risk of mucositis (p < 0.001). Patients who did not initiate early prophylaxis with conservative measures developed mucositis earlier (p < 0.05).
Conclusions
The incidence of mucositis is high, being reported mainly in AL patients, with limitations in quality of life. Grade 4 neutropenia increases mucositis risk. Early prophylaxis with basic oral care may delay mucositis. Further studies are crucial to characterize mucositis epidemiology, physiopathology, and its management.
Similar content being viewed by others
References
Peterson D, Bensadoun R, Roila F (2011) Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol 22(6):78–84
Niscola P, Romani C, Cupelli L, Scaramucci L, Tendas A, Dentamaro T, Amadori S, Fabritiis P (2007) Mucositis in patients with hematologic malignancies: an overview. Haematologica 92:222–231
World Health Organization (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva
Stiff P (2001) Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 27(2):3–11
Stiff P, Erder H, Bensinger W, Emmanouilides C, Gentile T, Isitt J, Lu Z, Spielberger R (2006) Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 37:393–401
Peterson D, Lalla R (2010) Oral mucositis: the new paradigms. Curr Opin Oncol 22:318–322
Niscola P, Arcuri E, Giovannini M, Scaramucci L, Romani C, Palombi F, Trapè G, Morabito F (2004) Pain syndromes in haematological malignancies: an overview. Hematol J 5:293–303
Elting LS, Shih YC, Stiff PJ, Bensinger W, Cantor SB, Cooksley C, Spielberger R, Emmanoulides C (2007) Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant 13:806–813
Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB (2003) The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531–1539
Rosenthal DI (2007) Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes. J Support Oncol 5:23–31
Avritscher E, Cooksley C, Elting LS (2004) Scope and epidemiology of cancer therapy-induced oral and gastrointestinal mucositis. Semin Oncol Nurs 1:3–10
Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB (2004) Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology—perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology and consequences for patients. Cancer 100(9):1995–2005
National Institutes of Health/National Cancer Institute—U.S. Department of health and human services (2010) Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03, 33
Bulecheck G, Butcher H, Dochterman J (2010) Nursing Interventions Classification (NIC), 5th edn. Elsevier, USA
Elting LS, Cooksley CD, Chambers MS, Garden AS (2007) Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 68:1110–1120
Douglas EP, Rajesh VL (2010) Oral mucositis: the new paradigms. Curr Opin Oncol 22:318–322
Al-Dasooqi N, Sonis ST, Bowen JM et al (2013) Emerging evidence on the pathobiology of mucositis. Support Care Cancer 21:2075–2083
McGuire D, Fulton J, Park J, Brown CG, Correia MEP, Eilers J, Elad S, Gibson F, Oberle-Edwards LK, Bowen J, Lalla R (2013) Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 21:3165–3177
Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831
Acknowledgments
The authors acknowledge all patients and oncological hematologic staff for cooperating with this observational study.
No support or grant was used by the authors.
Conflict of interest
All authors have no conflict of interest. The authors have full control of all primary data and agree to allow the journal to review the data if requested.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Martinez, J.M., Pereira, D., Chacim, S. et al. Mucositis care in acute leukemia and non-Hodgkin lymphoma patients undergoing high-dose chemotherapy. Support Care Cancer 22, 2563–2569 (2014). https://doi.org/10.1007/s00520-014-2199-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-014-2199-y